Risk factors for CRB and MB at study inclusion in patients without anticoagulation
| . | CRB . | MB . | ||
|---|---|---|---|---|
| SHR . | 95% CI . | SHR . | 95% CI . | |
| Age (continuous per increase of 1, y) | 0.99 | 0.98-1.01 | 1.01 | 0.99-1.03 |
| BMI (continuous per increase of 1, kg/m2) | 0.97 | 0.95-1.01 | 0.98 | 0.94-1.02 |
| Hemoglobin (continuous per increase of 1, mg/dL) | 0.88 | 0.79-0.98 | 0.79 | 0.67-0.92 |
| Platelets (continuous per increase of 10, ×109/L) | 1.02 | 1.00-1.03 | 1.01 | 0.98-1.04 |
| Leucocytes (continuous per increase of 1, ×109/L) | 1.03 | 0.98-1.07 | 0.99 | 0.91-1.07 |
| Creatinine (continuous per increase of 1, mg/dL) | 1.09 | 0.92-1.30 | 1.09 | 0.82-1.46 |
| Albumin (continuous per increase of 1, g/L) | 0.95 | 0.92-0.99 | 0.91 | 0.87-0.95 |
| Aspartate transaminase (U/L, per increase of 10) | 1.02 | 1.00-1.04 | 1.03 | 1.00-1.05 |
| Alanine transaminase (U/L, per increase of 10) | 1.02 | 0.99-1.05 | 1.03 | 1.00-1.06 |
| Alkaline phosphatase (U/L, per increase of 10) | 1.01 | 0.99-1.02 | 1.02 | 1.00-1.03 |
| Stage IV (vs I, II, and III) | 0.53 | 0.35-0.79 | 0.72 | 0.38-1.37 |
| Head and neck vs other cancer type | 2.38 | 1.46-3.88 | 3.16 | 1.65-6.03 |
| GI vs other cancer type | 1.06 | 0.68-1.66 | 1.02 | 0.50-2.07 |
| Luminal GI vs other cancer type | 1.13 | 0.66-1.94 | 0.76 | 0.30-1.93 |
| Pancreas vs other cancer type | 0.76 | 0.33-1.72 | 1.48 | 0.58-3.78 |
| Lung vs other cancer type | 0.98 | 0.62-1.55 | 0.55 | 0.24-1.21 |
| Presence of recurrent/progressive cancer | 1.05 | 0.71-1.57 | 1.63 | 0.89-2.97 |
| First line vs other treatment line | 0.96 | 0.65-1.43 | 0.60 | 0.33-1.11 |
| Palliative therapy vs curative therapy | 1.19 | 0.55-2.56 | 1.32 | 0.41-4.26 |
| History of any bleeding | 1.49 | 0.89-2.49 | 1.09 | 0.49-2.46 |
| . | CRB . | MB . | ||
|---|---|---|---|---|
| SHR . | 95% CI . | SHR . | 95% CI . | |
| Age (continuous per increase of 1, y) | 0.99 | 0.98-1.01 | 1.01 | 0.99-1.03 |
| BMI (continuous per increase of 1, kg/m2) | 0.97 | 0.95-1.01 | 0.98 | 0.94-1.02 |
| Hemoglobin (continuous per increase of 1, mg/dL) | 0.88 | 0.79-0.98 | 0.79 | 0.67-0.92 |
| Platelets (continuous per increase of 10, ×109/L) | 1.02 | 1.00-1.03 | 1.01 | 0.98-1.04 |
| Leucocytes (continuous per increase of 1, ×109/L) | 1.03 | 0.98-1.07 | 0.99 | 0.91-1.07 |
| Creatinine (continuous per increase of 1, mg/dL) | 1.09 | 0.92-1.30 | 1.09 | 0.82-1.46 |
| Albumin (continuous per increase of 1, g/L) | 0.95 | 0.92-0.99 | 0.91 | 0.87-0.95 |
| Aspartate transaminase (U/L, per increase of 10) | 1.02 | 1.00-1.04 | 1.03 | 1.00-1.05 |
| Alanine transaminase (U/L, per increase of 10) | 1.02 | 0.99-1.05 | 1.03 | 1.00-1.06 |
| Alkaline phosphatase (U/L, per increase of 10) | 1.01 | 0.99-1.02 | 1.02 | 1.00-1.03 |
| Stage IV (vs I, II, and III) | 0.53 | 0.35-0.79 | 0.72 | 0.38-1.37 |
| Head and neck vs other cancer type | 2.38 | 1.46-3.88 | 3.16 | 1.65-6.03 |
| GI vs other cancer type | 1.06 | 0.68-1.66 | 1.02 | 0.50-2.07 |
| Luminal GI vs other cancer type | 1.13 | 0.66-1.94 | 0.76 | 0.30-1.93 |
| Pancreas vs other cancer type | 0.76 | 0.33-1.72 | 1.48 | 0.58-3.78 |
| Lung vs other cancer type | 0.98 | 0.62-1.55 | 0.55 | 0.24-1.21 |
| Presence of recurrent/progressive cancer | 1.05 | 0.71-1.57 | 1.63 | 0.89-2.97 |
| First line vs other treatment line | 0.96 | 0.65-1.43 | 0.60 | 0.33-1.11 |
| Palliative therapy vs curative therapy | 1.19 | 0.55-2.56 | 1.32 | 0.41-4.26 |
| History of any bleeding | 1.49 | 0.89-2.49 | 1.09 | 0.49-2.46 |
BMI, body mass index.